Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Moderna makes medicines that teach the body's own cells to fight disease, most famously its COVID-19 vaccine.
Moderna is a biotechnology company that sells one big thing right now: its mRNA medicines, above all the COVID-19 vaccine. Instead of growing a virus in a lab and killing it, Moderna writes a short genetic message — mRNA — that tells your cells to build a harmless piece of a virus. Your immune system sees that piece, learns to recognize it, and is ready if the real virus shows up. The body then destroys the message on its own. This is why the company could design a vaccine in days once the virus's genetic code was published.
The company was founded in 2010 in Cambridge, Massachusetts, on a then-radical idea: mRNA could be a plug-and-play platform, not just one drug. Change the message, and you change the disease you target. For years this was a money-losing research bet, funded by investors and partners rather than product sales. Then COVID-19 turned the platform into a global business almost overnight. The money story is unusually dramatic. Moderna booked about $18.4 billion in revenue in 2021 and roughly $19.3 billion in 2022, then watched sales collapse as the pandemic faded — revenue fell to about $6.8 billion in 2023 and around $3.2 billion in 2024. The company has been spending heavily on research while its COVID revenue shrinks, and it has posted large losses in the years since the peak. Its big bet now is a second product: an mRNA vaccine for RSV, approved in 2024 for older adults, plus late-stage work on flu, combination shots, and a rare disease therapy.
Moderna was built on a simple but wild idea: your body's cells read mRNA like a set of instructions, so if you could write your own instructions, you could tell cells to make drugs or vaccines for almost any disease. The catch was that raw mRNA set off alarms in the body, and the company's name comes from its fix: modified RNA. The science behind it came from the research of Katalin Karikó and Drew Weissman, who found a way to change mRNA so the body tolerated it.
Soon after, the company started actual research into mRNA medicines, and Stéphane Bancel came in as founding CEO. He would lead the place for more than a decade, which matters because the next ten years were mostly spending and promising, with nothing to sell.
By 2018 Moderna had no product on the market at all, yet it went public and raised $621 million — the largest biotech IPO on record at the time. Investors were paying for a platform, not a product: a bet that programmable mRNA could eventually become many drugs, not just one.
Then the pandemic hit, and Moderna's whole idea suddenly made sense to everyone. Once the virus's genetic sequence was published, the company designed a COVID-19 vaccine candidate from it and started clinical trials, helped by $483 million from Operation Warp Speed. The vaccine got Emergency Use Authorization, and a company few outside biotech had heard of became a household name.
The emergency green light became a full one when the FDA fully approved SPIKEVAX, Moderna's COVID-19 vaccine. It was the first product in company history to receive full approval — the platform finally had a real, approved medicine behind it.
Moderna then got its RSV vaccine, mRESVIA, approved in the U.S., Europe, Canada and Qatar. It was only the company's second product ever, but that was the point: it showed the mRNA platform could work beyond COVID-19.
The problem was that demand for COVID vaccines collapsed, and the losses kept widening. The stock fell to a historic low of $22.28, down more than 95 percent from its peak. To survive, Moderna cut about a tenth of its workforce and dropped several programs — a company that had been swimming in cash was suddenly fighting for its life.
That fight got its first real hope in 2026, when intismeran — a personalized mRNA cancer therapy developed with Merck — met its Phase 3 goals in melanoma. It was the first positive late-stage result ever for an mRNA-based cancer therapy, and it pushed investors to ask a bigger question: maybe this company can be more than a respiratory vaccine maker after all.
The real question is whether Moderna is a one-hit pandemic story or a genuine platform. It competes with giant rivals like Pfizer and BioNTech in mRNA, and its RSV shot goes up against Pfizer and GSK. Its advantages are speed and a manufacturing base it built during COVID; its weakness is that vaccine demand is seasonal, price-sensitive, and politically messy. The company is also cutting costs and shrinking its pipeline to conserve cash. In short: a science-first firm trying to prove its engine works without a once-in-a-century emergency pushing the gas pedal.
Saved answer · last researched 1 Nov 2026